Valneva SE

INRLF·OTC Markets OTCPK·Healthcare

FollowCompareShare

3.37000.0000 (0.00%)today

At close: Oct 16, 4:00 PM EDT · May be delayed up to 15 min · USD

1D5D1M6MYTD1Y5Y10Y20YAll

MountainLineCandles

Indicators

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close3.3700

Open3.0000

Day range3.00003.3700

52-week range2.43005.9000

Off day high0.00%

Off 52-week high−42.88%

Volume602

Avg. volume (3M)32.00

Market cap639.11M

EPS (TTM)-1.05

Forward P/E—

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)1.26

Shares outstanding189.65M

Short interest—

Earnings dateAug 13, 2026

Analyst target—

Profit margin−110.29%

Related companies

Compare ›

Also watched

What visitors to Valneva's page also look at.

Company	Mkt cap	Price	Today
VALNValneva SEVALN	531.96M	5.61	−5.08%
CASBCANSINO BIOLOGICS INCCASBF	827.60M	3.3500	0.00%
OXBDOxford Biomedica PLCOXBDF	837.69M	6.92	+3.28%
IDRSIDORSIA LTDIDRSF	1.45B	5.38	0.00%
PTCHPureTech Health PLCPTCHF	362.87M	1.4800	0.00%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All INRLF news ›

Stock Titan·4d ago

Valneva plans US and Europe healthcare investor talks

Valneva (VALN) expects decisions on its Pfizer-partnered Lyme vaccine candidate within 12 months Stock Titan Valneva plans US and Europe healthcare investor talks Valneva plans to discuss the partnered Lyme vaccine’s regulatory outlook,…

Pluang·4d agoPositive

Valneva to present Lyme vaccine updates at US and European investor conferences

Valneva SE announced that its senior management will present and hold meetings with institutional investors at upcoming healthcare conferences in the US and Europe. The company will focus on discussing the regulatory outlook for its Lyme…

MarketScreener·Oct 12

Bolloré, Exail, Kering, Valneva, Virbac... stocks to watch today in Paris

Published on 03/18/2026 at 04:04 am EDT Kering: Gaining traction, capped by industry headwinds October 08, 2026 at 06:10 am EDT Humana Lower on Profit Guidance; P&G Moves on Results | Stock Movers Kering bets on jewelry to revive growth

Stock Titan·Oct 8Negative

Valneva’s IXCHIQ loses UK marketing authorization

A UK vaccine decision won't be appealed by Valneva (VALN), which expects minimal sales impact. Stock Titan Valneva’s IXCHIQ loses UK marketing authorization Valneva expects the UK revocation to have only minimal overall sales impact and no…

Seeking Alpha·Oct 7Negative

Valneva falls as UK revokes marketing authorization for chikungunya vaccine

Valneva stock drops after UK MHRA revokes Ixchiq chikungunya vaccine authorization over safety concerns. Read more here. Kitsawet Saethao/iStock via Getty Images - Valneva SE (VALN) is down ~5% in after-hours trading Wednesday after it…

@capitalcom·Oct 5Negative

Valneva stock forecast: EMA validates Lyme vaccine application

As of 10:15am UTC on 16 September 2026, Valneva SE (VLA) traded at €2.86, within an intraday range of €2.79–€2.88. Past performance is not a reliable indicator of future results. Recent developments include the European Medicines Agency’s…

From articles in the 4Search news index.

In the news

6mentions in 30 days

6with it in the headline

Negativesentiment

Mentioned with

European Medicines Agency5Pfizer5Moderna3Sanofi3U.S. Food and Drug Administration3Chemocentryx2Csl Vifor2Eli Lilly2

People in the coverage

Moderna4Stifel4Thomas Lingelbach4Valneva4Donald Trump3Annaliesa Anderson2

Themes

FDA4Biotechnology3Health3Valn3Europe2Healthcare26-K1All News and Stock Ideas1

Most coverage from

1. stocktitan.net2
2. capital.com1
3. marketscreener.com1
4. pluang.com1
5. seekingalpha.com1

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.